Dyadic International’s Earnings Call Shows Early Momentum

Dyadic International Inc. ((DYAI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Dyadic International’s latest earnings call struck a cautiously optimistic tone, blending sharp year‑over‑year revenue gains and tangible commercial milestones with clear reminders that the company is still early in its commercialization journey and far from profitability. Management emphasized disciplined cash use and diversified revenue streams, yet investors were warned about ongoing losses, rising costs and execution risks tied to partner‑driven growth.

Strong Revenue Growth

Dyadic reported first‑quarter 2026 revenue of about $1.1 million, up 182% from roughly $394,000 a year earlier, marking a notable acceleration for an early‑stage platform company. The surge was fueled by around $220,000 of R&D revenue, roughly $277,000 in grant income and about $200,000 of milestone revenue, underscoring the contribution of partnerships to the top line.

Commercial Product Launches and Shipments

Several products have moved from development into commercial channels, signalling progress toward recurring revenue. Proliant launched Albufree Dx with Dyadic entitled to profit‑sharing, while Inzymes commercialized recombinant bovine chymosin, Fermbox EN3ZYME fulfilled a large‑scale order and recombinant animal‑origin‑free DNase‑1 entered the market alongside shipments of DNase‑1 and bovine transferrin to an OEM distributor.

Distribution and Partner Expansion

The company expanded its commercial reach through an OEM distribution agreement with IBT Bioservices that opens global channels for DNase‑1 and transferrin. Dyadic also broadened its partnership with Intralink to cover Europe, building on earlier success in Japan and allowing faster customer sampling and qualification without heavy internal commercial spending.

Grant Funding and Biopharma Validation

Non‑dilutive funding remains a pillar of Dyadic’s strategy, with a roughly $3 million program backed by a major foundation and a collaboration with CEPI that could provide up to about $2.4 million. These programs finance monoclonal antibody and vaccine antigen work that has produced data showing comparability to traditional CHO‑derived antibodies, strengthening confidence in the C1 platform.

Platform Clinical and Preclinical Data

Management highlighted that a Phase I human study of a C1‑produced protein has been completed, demonstrating safety in humans and helping to de‑risk the technology. Additional nonhuman primate studies with monoclonal antibodies add preclinical support, positioning Dyadic to pursue more partner‑driven biopharma opportunities that could translate into future royalties and licensing income.

Early Commercial Traction in Target Markets

Initial purchase orders for recombinant bovine transferrin point to early traction in cultivated meat and broader cell culture applications, even if current volumes are modest. A collaboration with BRIG BIO to develop recombinant bovine alpha‑lactalbumin is advancing toward customer sampling expected around mid‑2026, while sampling of bioindustrial products is expanding across Asia Pacific.

Improved Operating Losses and Disciplined Cash Management

Despite remaining in the red, Dyadic showed incremental financial improvement with loss from operations narrowing about 5% year over year to roughly $1.9 million. Net loss improved to approximately $1.95 million, or $0.05 per share, and the company ended the quarter with around $6.6 million in cash and securities, supporting a runway into the second quarter of 2027 under current burn assumptions.

Multiple Revenue Pathways

The company stressed that its business model is built on diversified revenue channels that span direct product sales and OEM distribution to milestone payments, profit‑sharing and licensing. These pathways cut across life sciences, food and nutrition and bioindustrial markets, reducing dependence on any single product or end market and potentially smoothing revenue volatility over time.

Rising Cost of Revenue

The flip side of higher activity was a sharp increase in cost of revenue, which rose to about $792,000 from roughly $298,000, an increase of around 166%. Management attributed this jump primarily to elevated R&D and grant‑funded program activity, particularly under CEPI and foundation‑backed initiatives, which support long‑term platform validation but weigh on near‑term margins.

G&A Expense Increase

General and administrative expenses climbed by about $159,000, or 10% year over year, to approximately $1.8 million as Dyadic invested in legal, accounting and rebranding efforts along with business development. These costs were partially offset by lower share‑based compensation and insurance, but they highlight the overhead required to support a broader commercial and partnership footprint.

Still Operating at a Net Loss

Even with top‑line growth and cost discipline, Dyadic remains firmly unprofitable and far from scale, posting a quarterly net loss of about $1.95 million against only $1.1 million of revenue. Management acknowledged that absolute revenue levels remain modest and that reaching breakeven will require significant ramp‑up in product sales and partner‑derived income over the coming years.

Revenue Largely Early‑Stage and Grant/Milestone‑Dependent

A large portion of current revenue still comes from R&D reimbursements, grants and milestone recognition rather than steady product demand, underscoring the early‑stage nature of the business. While anticipated royalties and partner‑driven revenues are progressing through the pipeline, they had not materially contributed in the first quarter and remain a key execution area for investors to monitor.

Uncertain and Graduated Ramp for Key Products

Management tempered expectations around recombinant bovine transferrin by signalling a gradual rather than explosive ramp, with current orders limited to small kilogram‑scale pilot volumes. Significant volume growth hinges on regulatory approvals and commercialization timelines for cultivated meat and related applications, adding a layer of uncertainty to long‑term demand forecasts.

Dependence on Partners and External Manufacturing/Distribution

Dyadic’s asset‑light commercialization strategy leans heavily on partners such as Fermbox, IBT, Intralink and BRIG BIO as well as outsourced manufacturing and distribution to scale its products. While this approach reduces capital needs, it also limits the company’s direct control over pricing, timing and execution, introducing dependency risks that could affect both margins and the pace of revenue realization.

Cash Position Requires Ongoing Discipline and Potential Financing

With roughly $6.6 million in cash and an expected 2026 burn in line with or below last year’s sub‑$5.7 million level, Dyadic projects liquidity into the second quarter of 2027. However, management signalled that strategic partnerships and capital market options remain on the table, implying that additional financing could be needed if commercialization momentum fails to accelerate, raising the prospect of future dilution.

Forward‑Looking Guidance and Outlook

Looking ahead, Dyadic expects 2026 revenue growth to be driven by continued product shipments through IBT, including DNase‑1 and transferrin, and by the first bioindustrial royalties expected during the year. The company aims to keep operating expenses broadly aligned with 2025 levels while maintaining a similar or lower cash burn, suggesting a focus on controlled growth alongside incremental scaling of partner‑linked revenue streams.

Dyadic’s earnings call painted the picture of a platform company in transition, moving from validation to early commercialization while still grappling with the realities of small scale and partner‑dependent execution. For investors, the story hinges on whether the expanding product portfolio, diversified revenue paths and strong grant‑backed validation can outpace rising costs and financing needs as the company marches toward sustainable profitability.